AMGN Stock Recent News

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market

Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2025 Healthcare Conference Call May 14, 2025 12:20 PM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research and Development Conference Call Participants Tim Anderson - Bank of America Merrill Lynch Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. large pharma and biotech analyst at Bank of America.

President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.

Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.

The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.

THOUSAND OAKS, Calif. , May 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.

Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.

Claremont, CA, May 08, 2025 (GLOBE NEWSWIRE) -- During the Keck Graduate Institute commencement ceremony on May 17, 2025, Robert A. Bradway will receive an honorary Doctor of Philosophy in Applied Life Sciences degree in recognition of his significant leadership contributions to the biotechnology field.

CAMBRIDGE, England--(BUSINESS WIRE)--Today, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for TEPEZZA® (teprotumumab) as the first therapy specifically licensed for the treatment of adult patients with moderate-to-severe Thyroid Eye Disease (TED). Affecting approximately 50,000 people in the UK,1 TED is a progressive and potentially vision-threatening condition, which can cause eye bulging, double vision, eye pain, r.